QDEL Stock Crash: What QuidelOrtho's 27.5% Drop Tells Healthcare Investors
QuidelOrtho (NASDAQ: QDEL) dropped 27.5% on April 16, 2026, after announcing preliminary Q1 2026 revenue of $615M-$620M, a 9.3% miss versus the $680.6M consensus and an 11% YoY decline.
Three Causes
- Flu Season Collapse: US ILI visits fell 30%+ vs Q1 2025's record-high severity (290 pediatric deaths, CDC).
- China VBP Risk: Distributor order pullback ahead of potential NHSA pricing cuts.
- EMEA Delays: Middle East conflict disrupted regional shipments.
Why Abbott Survived
Abbott grew diagnostics +1.8% comparable in Q1 2026 by diversifying into oncology, core-lab (Alinity), and diabetes care. QDEL's respiratory concentration left it exposed. Abbott market cap: ~$210B vs QDEL's $1.19B.
Outlook
Base case: $11-$15 box range through Q4 2026. UBS cut target to $17 (from $30). FY2026 guidance of $2.7B-$2.9B requires flu normalization, no China VBP, and EMEA recovery simultaneously.
For the full analysis in Korean, visit Snakestock
